Pankti Reid MD, MPH

Pankti Reid, MD, MPH, is a rheumatologist whose practice primarily focuses on the evaluation and management of immune-related adverse events (irAEs) where cancer patients experience autoimmune conditions as a side effect of their cancer treatment. Dr. Reid also provides general rheumatology care and has expertise in evaluating and treating vasculitis, myositis, lupus, rheumatoid arthritis, systemic scleroderma, polymyalgia rheumatica, etc.

In an effort to improve care for her patients, Dr. Reid established a robust immune-related adverse event (irAE) clinical infrastructure that includes a clinic, an electronic referral system and an interdisciplinary clinical consortium. Additionally, she is developing an irAE curriculum aimed at improving training in this new area of medicine for internal medicine residents and oncology and rheumatology fellows.

In addition to the above, Dr. Reid has led multiple clinical trials studying the use of a commonly used rheumatic medication (tocilizumab) for COVID-19 hyperinflammation. She is also the Clinical Trial Director for the Division of Rheumatology at the University of Chicago.